Piramal Pharma Ltd. Updates Key Managerial Personnel Contact Details
Piramal Pharma Limited has updated the contact details for its Key Managerial Personnel, including CFO Vivek Valsaraj and Company Secretary Maneesh Sharma, as per SEBI regulations for disclosure purposes.
This is a standard compliance update and does not involve any significant corporate actions, financial results, or strategic changes that would materially impact the company's operations or stock price.
The announcement is a routine regulatory update regarding contact information for Key Managerial Personnel and does not contain any specific financial or operational news that would impact the company's sentiment.
Piramal Pharma Limited has provided updated contact details for its Key Managerial Personnel (KMP) as required under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These details are for determining the materiality of events or information and for making disclosures to the stock exchanges.
The updated contact information includes:
* Mr. Vivek Valsaraj, Chief Financial Officer, with email id vivek.valsaraj@piramal.com. * Mr. Maneesh Sharma, Company Secretary and Compliance Officer, with email id maneesh.sharma2@piramal.com.
This update is intended to ensure compliance with regulatory requirements for timely and accurate disclosures.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.